📣 Help Shape the Future of UKRI's Gateway to Research (GtR)

We're improving UKRI's Gateway to Research and are seeking your input! If you would be interested in being interviewed about the improvements we're making and to have your say about how we can make GtR more user-friendly, impactful, and effective for the Research and Innovation community, please email gateway@ukri.org.

Determining the recommended dose of pacritinib: results from the PAC203 dose-finding trial in advanced myelofibrosis. (2020)

First Author: Gerds AT

Attributed to: Unravelling signatures of clonal response, resistance and evolution of high-risk essential thrombocythaemia at single-cell resolution funded by MRC

Abstract

No abstract provided

Bibliographic Information

Digital Object Identifier: http://dx.doi.org/10.1182/bloodadvances.2020003314

PubMed Identifier: 33232476

Publication URI: http://europepmc.org/abstract/MED/33232476

Type: Journal Article/Review

Volume: 4

Parent Publication: Blood advances

Issue: 22

ISSN: 2473-9529